Ann Lee, Chief Technical Officer
Professional Overview
Ann Lee is an accomplished biotechnology executive with over 15 years of experience leading technical operations and development functions in the pharmaceutical and cell therapy industries. As the Chief Technical Officer at Prime Medicine, Inc., she is responsible for overseeing the company's technical strategy, manufacturing, and R&D operations to support the development of its gene editing platform.
Experience Summary
Current Role
As the Chief Technical Officer at Prime Medicine, Inc., Ann leads the company's technical functions, including process development, analytical sciences, manufacturing, and quality. She is instrumental in driving the advancement of Prime Medicine's gene editing technology and ensuring the seamless execution of its clinical programs.
Under Ann's technical leadership, Prime Medicine has made significant strides in optimizing its gene editing platform, achieving key manufacturing milestones, and expanding its pipeline of innovative therapeutic candidates.
Career Progression
Prior to joining Prime Medicine, Ann held various senior-level positions in the cell therapy and pharmaceutical domains. Most recently, she served as the SVP and Head of Cell Therapy Development and Operations (CTDO) at Bristol Myers Squibb, where she was responsible for the technical strategy and operational execution of the company's cell therapy pipeline.
Earlier in her career, Ann held executive roles at Celgene, Juno Therapeutics, and Genentech/Roche, where she led the technical operations, development, and manufacturing functions. Throughout her career, she has demonstrated a strong track record of driving strategic initiatives, enhancing operational efficiency, and delivering on critical development and commercialization goals.
Academic Background
Ann holds a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology (MIT) and a B.S. in Chemical Engineering from the University of California, Berkeley. Her academic background has provided her with a deep understanding of the technical complexities and scientific principles that underpin the biopharmaceutical industry.
Areas of Expertise
- Cell and gene therapy development and manufacturing
- Process development and optimization
- Analytical methods and quality control
- Technical strategy and operations management
- Cross-functional team leadership and collaboration
Professional Impact
Ann's technical expertise and leadership have been instrumental in advancing the development of innovative cell and gene therapies. She has played a pivotal role in the successful development and commercialization of several breakthrough therapies, contributing to improved patient outcomes and the overall progress of the biopharmaceutical industry.
Conclusion
With her extensive technical expertise, strategic vision, and proven track record of delivering results, Ann is well-positioned to drive the continued growth and success of Prime Medicine as it pioneers the next generation of gene editing technologies. Her commitment to innovation and her ability to navigate complex technical and operational challenges make her a valuable asset to the company and the broader biopharmaceutical industry.
